98%
921
2 minutes
20
A copper/low-density polyethylene nanocomposite (nano-Cu/LDPE), a potential intrauterine device component material, has been developed from our research. A logical extension of our previous work, this study was conducted to investigate the expression of plasminogen activator inhibitor 1 (PAI-1), substance P (SP), and substance P receptor (SP-R) in the endometrium of Sprague Dawley rats, New Zealand White rabbits, and Macaca mulatta implanted with nano-Cu/LDPE composite. The influence of the nano-Cu/LDPE composite on the morphology of the endometrium was also investigated. Animals were randomly divided into five groups: the sham-operated control group (SO group), bulk copper group (Cu group), LDPE group, and nano-Cu/LDPE groups I and II. An expression of PAI-1, SP, and SP-R in the endometrial tissues was examined by immunohistochemistry at day 30, 60, 90, and 180 postimplantation. The significant difference for PAI-1, SP, and SP-R between the nano-Cu/LDPE groups and the SO group (P<0.05) was identified when the observation period was terminated, and the changes of nano-Cu/LDPE on these parameters were less remarkable than those of the Cu group (P<0.05). The damage to the endometrial morphology caused by the nano-Cu/LDPE composite was much less than that caused by bulk copper. The nano-Cu/LDPE composite might be a potential substitute for conventional materials for intrauterine devices in the future because of its decreased adverse effects on the endometrial microenvironment.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3940689 | PMC |
http://dx.doi.org/10.2147/IJN.S56756 | DOI Listing |
Toxicol Appl Pharmacol
October 2025
WestChina-Frontier PharmaTech Co. (WCFP) & National Chengdu Center for Safety Evaluation of Drugs (NCCSED), Chengdu, Sichuan 610041, PR China.
Continuous dopaminergic stimulation (CDS) is a key strategy in Parkinson's disease (PD) treatment. We developed Rotigotine Behenate Extended-Release Microspheres (RBEM), an injectable 28-day sustained-release formulation that hydrolyzes in vivo to release active rotigotine, maintaining therapeutic levels. RBEM shows improved PK profiles-longer duration and more stable drug concentrations-versus existing CDS therapies.
View Article and Find Full Text PDFMalar J
July 2025
Emory Vaccine Center, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.
Background: Numerous caveola-vesicle complexes (CVCs) form around the surface of Plasmodium vivax and Plasmodium cynomolgi infected erythrocytes during the asexual cycle. They include a 95 kDa protein in both species, the Plasmodium helical interspersed subtelomeric (PHIST) protein (PHIST/CVC-81) located at the cytoplasmic face of CVC vesicles and tubules. The functions and detailed structure of CVCs are poorly understood, although they are essential for parasite survival.
View Article and Find Full Text PDFSci Rep
July 2025
College of Optometry, University of Houston, 4401 Martin Luther King Blvd, Houston, TX, 77204-2020, USA.
Dry eye disease (DED) is a common ocular condition that has been estimated to affect ~ 10 to 55.4% of the global population. Symptoms of DED include eye irritation, ocular pain and discomfort, inflammation, and photophobia, and, if left untreated, can lead to infection, corneal neuropathy, corneal scarring and impaired vision.
View Article and Find Full Text PDFFront Biosci (Landmark Ed)
March 2025
FibroX Therapeutics (Shanghai) Inc., 201203 Shanghai, China.
Background: Low back pain (LBP) is the leading cause of disability among the elderly, placing significant social and economic burdens on societies globally. A common cause of chronic LBP is lumbar disc degeneration. Previously, we reported that autologous or allogenic fibroblast injections could treat intervertebral disc degeneration (IVDD) in preclinical studies by maintaining disc height and stability through fibrosis.
View Article and Find Full Text PDFViruses
February 2025
Division of Medical Virology, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa.
We previously reported on HIV vaccines that elicited autologous Tier 2 neutralizing antibodies (nAbs) in rabbits. In the current study, we sought to establish a proof of concept that HIV vaccines using identical designs elicit Tier 2 nAbs in arhesus macaque (RM) model. DNA and MVA vaccines expressing SIV Gag and HIV-1 Env antigens were constructed, and in vitro expression was confirmed.
View Article and Find Full Text PDF